Background/Objectives: Few studies have focused on patients with immune-related adverse events (irAEs) after immune checkpoint inhibitor (ICI) treatment who were cared for primarily by hospitalists. The objective of our study was to describe the patterns and outcomes of adult solid-tumor cancer patients admitted to our onco-hospital medicine service.Methods: We retrospectively reviewed patients with solid tumors who received ICIs and were admitted to our service in 2021–2022 with an irAE and compared them to a control group (IOTOX vs. NO IOTOX, respectively). The primary outcome was the patterns of irAEs requiring hospitalization; secondary outcomes included 30-day emergency room visit, readmission, and 30-day mortality.Results: There were 144 patients in the IOTOX group and 286 controls. The most common tumor type was lung and thoracic malignancies (62, 43.1%). The most common ICI causing the irAEs was pembrolizumab (66, 45.8%). The most common irAEs were pneumonitis (49, 34%), colitis (28, 19.4%), hepatitis (18, 12.5%), and myocarditis (16, 11.1%). Of the 144 patients, eight (6%) died from the hospitalization irAE. Fifteen (15.6%) had an ER visit within 30 days due to the same irAE, and thirteen (13.7%) were readmitted. Survival at 30 days after discharge did not differ significantly between groups.Conclusions: Despite many patients having severe irAEs and irAEs associated with higher mortality, they generally had a favorable outcome compared to the literature.
背景/目的：目前针对主要由住院医师管理的免疫检查点抑制剂治疗后发生免疫相关不良事件患者的研究较少。本研究旨在描述我院肿瘤内科收治的成人实体瘤癌症患者的免疫相关不良事件模式及临床结局。方法：我们回顾性分析了2021-2022年间接受免疫检查点抑制剂治疗后因免疫相关不良事件入院的实体瘤患者，并将其与对照组进行比较。主要观察指标为需要住院治疗的免疫相关不良事件类型；次要观察指标包括30天内急诊就诊率、再入院率及30天死亡率。结果：免疫相关不良事件组144例，对照组286例。最常见的肿瘤类型为肺部及胸部恶性肿瘤（62例，43.1%）。引发免疫相关不良事件最常见的免疫检查点抑制剂是帕博利珠单抗（66例，45.8%）。最常见的免疫相关不良事件包括肺炎（49例，34%）、结肠炎（28例，19.4%）、肝炎（18例，12.5%）和心肌炎（16例，11.1%）。144例患者中有8例（6%）因免疫相关不良事件住院期间死亡。15例（15.6%）因相同免疫相关不良事件在30天内急诊就诊，13例（13.7%）再次入院。两组患者出院后30天生存率无显著差异。结论：尽管许多患者出现严重免疫相关不良事件且部分事件与较高死亡率相关，但与文献报道相比，本组患者总体预后良好。
肿瘤(癌症)患者之家